Brigham and Women's Hospital

Dr. Peter Marks of FDA to Keynote 2023 Bio Innovation Conference Hosted by Maryland Life Sciences

Retrieved on: 
Lundi, avril 17, 2023
Stem Cells, Biotechnology, Technology, FDA, Health, Pharmaceutical, Oncology, Other Science, Other Technology, Genetics, Science, Vaccine, Molecular biology, Wuhan Institute of Biological Products, Yale University, Internal medicine, CBER, Physician, Brigham and Women's Hospital, Center for Biologics Evaluation and Research, Convention center, Medicine, Food and Drug Administration, Marks, National academy, National Academy of Medicine, Patient, Blood, Hospital, American College, Conference, Food, Safety, Pharmaceutical industry, Medical device, Nursing, Hematology, New York University, Research

Maryland Life Sciences, a division of the Maryland Tech Council, is pleased to announce that Peter Marks, Ph.D., Director of the Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration (FDA), will serve as keynote speaker at the 2023 Bio Innovation Conference on Monday, October 30, 2023 at the Bethesda North Marriot and Conference Center.

Key Points: 
  • Maryland Life Sciences, a division of the Maryland Tech Council, is pleased to announce that Peter Marks, Ph.D., Director of the Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration (FDA), will serve as keynote speaker at the 2023 Bio Innovation Conference on Monday, October 30, 2023 at the Bethesda North Marriot and Conference Center.
  • He joined the FDA in 2012 as Deputy Center Director for CBER and became Center Director in 2016.
  • Dr. Marks received his graduate degree in cell and molecular biology and his medical degree at New York University.
  • Dr. Marks is board certified in internal medicine, hematology and medical oncology, and is a Fellow of the American College of Physicians.

HDAX THERAPEUTICS ANNOUNCES APPOINTMENT OF DRS. ROMAN FLECK AND NEAL I. MUNI TO BOARD OF DIRECTORS

Retrieved on: 
Mardi, avril 11, 2023
Wyss Institute for Biologically Inspired Engineering, GSK, Venture, Drug development, Therapy, Heart failure, Doctor of Philosophy, Harvard University, Biotechnology, Brigham and Women's Hospital, Cardiovascular disease, DRS, MBA, MIT, Inflammation, HDAX, CMRA, Harvard Medical School, Boehringer Ingelheim, Entrepreneurship, Diabetic neuropathy, Hospital, MISSISSAUGA, Disease, Pharmaceutical industry, Medical device, Amgen, Medicine

MISSISSAUGA, ON, April 11, 2023 /PRNewswire/ -- HDAX Therapeutics, Inc., ("HDAX"), a privately-held pharmaceutical company developing therapeutics for neurological and cardiac diseases stemming from microtubule dysfunction, today announced the appointment of Roman Fleck, Ph.D. as Executive Chairman of the Board and Neal I. Muni, M.D., MSPH, as an independent Board member.

Key Points: 
  • MISSISSAUGA, ON, April 11, 2023 /PRNewswire/ -- HDAX Therapeutics, Inc., ("HDAX"), a privately-held pharmaceutical company developing therapeutics for neurological and cardiac diseases stemming from microtubule dysfunction, today announced the appointment of Roman Fleck, Ph.D. as Executive Chairman of the Board and Neal I. Muni, M.D., MSPH, as an independent Board member.
  • Muni and Fleck to the HDAX Board," said Nabanita Nawar, Ph.D., CEO and Co-Founder of HDAX.
  • "I am delighted to join the HDAX Board at such an exciting inflection point in the company's history," said Dr. Neal Muni.
  • Dr. Roman Fleck added, "HDAX's novel molecules feature unique properties which allow them to go after these diseases in ways not possible before."

Stanford Medicine Children's Health Welcomes New Chief of Pediatric Neurosurgery

Retrieved on: 
Lundi, mars 27, 2023
Heart, Partnership, Mayo Clinic, Boston Children's Hospital, University, Georgetown University, Brigham, MD, Patient, Hospital, Health, Brigham and Women's Hospital, Education, Nursing, Neurosurgery

In his new role, Dr. Maher will oversee the pediatric neurosurgery department, which combines nurturing care with innovative, cutting-edge research.

Key Points: 
  • In his new role, Dr. Maher will oversee the pediatric neurosurgery department, which combines nurturing care with innovative, cutting-edge research.
  • "I am thrilled to welcome Dr. Maher to Stanford Medicine Children's Health," said Dennis Lund, MD , Chief Medical Officer of Stanford Medicine Children's Health.
  • "I'm so excited to be here at Stanford Medicine Children's Health," Dr. Maher said.
  • Following residency, he moved to Boston for a fellowship in pediatric neurosurgery at Boston Children's Hospital and then completed another fellowship in cerebrovascular neurosurgery at Brigham & Women's Hospital.

Cardiometabolic Health Congress Announces Spring Conference Focused on Inflammation and Cardiometabolic Disease

Retrieved on: 
Jeudi, mars 16, 2023
Cancer, Health, DSM-IV codes, Education, Hospital, Gaylord Palms Resort & Convention Center, Inflammation, Heart failure, American Academy of Anti-Aging Medicine, Myocardial infarction, American Academy, Patient, Conditional sentence, Atherosclerosis, Convention center, Ageing, Cardiology, Faculty, Student, A4M, CMHC, Étienne-Émile Baulieu, Diabetes, Brigham and Women's Hospital, Stroke, News, Oxidative stress, Pharmaceutical industry, Nursing, MD

Concurrently delivered sessions throughout the weekend will all address a central driving force in the development of hundreds of chronic conditions - Inflammation.

Key Points: 
  • Concurrently delivered sessions throughout the weekend will all address a central driving force in the development of hundreds of chronic conditions - Inflammation.
  • Low-grade, chronic and systemic inflammation is associated with the development of cardiometabolic diseases, including myocardial infarction, stroke, diabetes, heart failure, accelerated aging, cancer, neurodegenerative, and many other health conditions.
  • The CMHC conference, Taming the Flames: Inflammation in Cardiometabolic Disease , will feature world-renowned experts as they present evidence and advances in the prevention and treatment of cardiometabolic disease with a special focus on inflammation.
  • Cardiometabolic Health Congress (CMHC) is committed to creating education for practicing clinicians, students, and patients interested in the quickly evolving field of cardiometabolic health.

Mediar Therapeutics Announces $105 Million Financing to Advance Portfolio of First-in-Class Fibrosis Therapies

Retrieved on: 
Mercredi, mars 15, 2023
Research, Blood, Therapy, Pfizer, Bristol Myers Squibb, Pathology, Partnership, Fibrosis, Mass, Patient, Death, Inflammation, Brigham and Women's Hospital, MBA, Disease, Massachusetts General Hospital, Eli Lilly and Company, Hospital, Sofinnova, HIV disease progression rates, Vaccine, Pharmaceutical industry, Linking and intrusive R, Imara

CAMBRIDGE, Mass., March 15, 2023 /PRNewswire/ -- Mediar Therapeutics Inc., a biotechnology company advancing a portfolio of first-in-class therapies that halt and even reverse the course of fibrosis, today announced a $105M financing, including a recent $85 million Series A round co-led by Novartis Venture Fund and Sofinnova Partners and with participation from Pfizer Ventures, Mission BioCapital, Gimv, Pureos, Bristol Myers Squibb, Eli Lilly & Company, Ono Venture Investment and Mass General Brigham Ventures. Mediar was founded on pioneering fibrosis research from Mass General and Brigham and Women's Hospitals in partnership with Mass General Brigham Ventures with the goal to transform the treatment of fibrotic disease by targeting the myofibroblast, the key cell type driving fibrosis progression. Mediar is led by industry veterans, Chief Executive Officer Rahul Ballal, Ph.D. and Chief Scientific Officer Paul Yaworsky, Ph.D. Dr. Ballal joins Mediar with nearly 20 years of experience in biotech and was most recently CEO of Imara, which recently merged with Enliven Therapeutics. Dr. Yaworsky joined Mediar in 2019 after a successful 21-year career at Pfizer, most recently serving as the COO of inflammation and immunology research. Joining the Mediar board is Nandita Shangari, Ph.D., from Novartis Venture Fund, Maina Bhaman, MBA, from Sofinnova Partners, and Andreas Jurgeit, Ph.D., from Gimv.

Key Points: 
  • Dr. Yaworsky joined Mediar in 2019 after a successful 21-year career at Pfizer, most recently serving as the COO of inflammation and immunology research.
  • Joining the Mediar board is Nandita Shangari, Ph.D., from Novartis Venture Fund, Maina Bhaman, MBA, from Sofinnova Partners, and Andreas Jurgeit, Ph.D., from Gimv.
  • He continued, "We are also progressing promising leads from our two other first-in-class portfolio programs into preclinical in-vivo proof-of-concept studies."
  • Current therapeutic approaches mainly focus on the initiators of fibrosis that modulate the underlying immune responses known to drive disease onset.

Can Seven Healthy Habits Now Reduce Risk of Dementia Later?

Retrieved on: 
Mardi, février 28, 2023
Parkinson's disease, Blood pressure, Female, Social media, American Academy of Neurology, Brigham and Women's Hospital, News, Diagnosis, Nervous system, AAN, Health, Life, Migraine, Annual general meeting, Risk, Brain, Research, American Heart Association, Alzheimer's disease, DSM-IV codes, Dementia, Medicare, Habit, Hospital, Epilepsy, Doctor of Science, Education, Bangladesh Technical Education Board, Multiple sclerosis, Stroke, Smoking, Concussion, American Academy, Dietary supplement, Residential care, Birth control, Pharmaceutical industry, Neurology

MINNEAPOLIS, Feb. 28, 2023 /PRNewswire/ -- New research that followed female participants for two decades has found that seven healthy habits and lifestyle factors may play a role in lowering the risk of dementia.

Key Points: 
  • MINNEAPOLIS, Feb. 28, 2023 /PRNewswire/ -- New research that followed female participants for two decades has found that seven healthy habits and lifestyle factors may play a role in lowering the risk of dementia.
  • "The good news is that making healthy lifestyle choices in middle age may lead to a decreased risk of dementia later in life."
  • After 20 years of follow-up, researchers looked at Medicare data to identify those who had been diagnosed with dementia.
  • After adjusting for factors like age and education, researchers found that for every increase of one point in the score, a participant's risk of dementia decreased by 6%.

The Latest Discoveries in Rheumatology Research at the Arthritis National Research Foundation 2023 Research Scholar Symposium

Retrieved on: 
Jeudi, février 23, 2023
FACP, Arthritis, Brigham and Women's Hospital, DVM, Janssen Pharmaceuticals, Ankylosing spondylitis, Infection, Immunity, ISCB Senior Scientist Award, Pfizer, Research, Patient, AM, Doctor of Philosophy, Inflammation, Harvard Medical School, Symposium, SVP, Neurology, CSO, Hospital, Pharmaceutical industry, MD

BOSTON, Feb. 23, 2023 /PRNewswire/ -- The Arthritis National Research Foundation (ANRF) 2023 Research Scholar Symposium on March 11th, 8 AM - 5 PM at the Hyatt Regency Boston, offers attendees exposure to cutting-edge research they cannot find anywhere else.

Key Points: 
  • This day-long Symposium features current scholars poised to share their discoveries in arthritis and other autoimmune diseases alongside industry expert presentations.
  • BOSTON, Feb. 23, 2023 /PRNewswire/ -- The Arthritis National Research Foundation (ANRF) 2023 Research Scholar Symposium on March 11th, 8 AM - 5 PM at the Hyatt Regency Boston, offers attendees exposure to cutting-edge research they cannot find anywhere else.
  • For current ANRF Scholar Ruth Napier, Ph.D., the Symposium offers a chance to bridge data to outcomes, helping attendees understand how vital research is to the 58.5 million Americans with Arthritis hoping for a cure.
  • We each play an important part in changing the future of AS care, and I take mine pretty seriously."

Global In Vitro Fertilization (IVF) Market Report 2023: Increasing Median Age of First-Time Mothers Drives Growth

Retrieved on: 
Jeudi, février 23, 2023
Ovulation, Infertility, Biomedical engineering, Female, Knowledge, Clinical, Brigham and Women's Hospital, IVF, Patient, The Cooper Companies, Primary ovarian insufficiency, Artificial intelligence, ALF, Physician, Maintenance, Laboratory, Fertilisation, Tubing (recreation), Research, Massachusetts General Hospital, Oocyte, ART, Fertility clinic, AI, Child, Growth, Generate, Uterine fibroid, Incubator, Male, HSA, Woman, Single, Hospital, Birth control, Medical device

DUBLIN, Feb. 23, 2023 /PRNewswire/ -- The "Global In Vitro Fertilization (IVF) Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 23, 2023 /PRNewswire/ -- The "Global In Vitro Fertilization (IVF) Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.
  • Growing public understanding and acceptance of infertility treatment will encourage the use of in vitro fertilization (IVF) methods, which will accelerate the development of the in vitro fertilization (IVF) market.
  • However, the main factor limiting the potential market for in vitro fertilization (IVF) is the cost of the treatments, which is well-known around the world.
  • The effective use of contraceptives has also significantly influenced the median age of first-time mothers, and this is anticipated to significantly fuel the expansion of the in vitro fertilization (IVF) market.

Melax Tech and Boston Academic Center Hospital Awarded $2.5 Million Joint Grant from the National Institute of Health (NIH)

Retrieved on: 
Jeudi, février 16, 2023
Cone Health Women's Hospital, Deep learning, Physician, Alzheimer's disease, Diagnosis, Bangladesh Technical Education Board, NIH, Social, Algorithm, Patient, Hospital, Health, National Institute on Aging, Brigham and Women's Hospital, CDS, NLP, EHR, Principal investigator, Electronic health record, Health information management, Dementia, Nursing, Medical device, Brigham

HOUSTON, Feb. 16, 2023 /PRNewswire/ -- Melax Tech, a world leader in biomedical natural language processing (NLP) technology, and Brigham and Women's Hospital, an academic medical center in Boston, has been awarded a two-year $2.5 million grant by the NIH.

Key Points: 
  • HOUSTON, Feb. 16, 2023 /PRNewswire/ -- Melax Tech, a world leader in biomedical natural language processing (NLP) technology, and Brigham and Women's Hospital, an academic medical center in Boston, has been awarded a two-year $2.5 million grant by the NIH.
  • The project aims to build and validate a clinical decision support system (CDS) for early cognitive decline detection.
  • This project is supported by the National Institute On Aging of the National Institutes of Health under Award Number R44AG081006.
  • The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Global Lupus Experts Recommend Changes to Clinical Trial Outcome Measures to Expedite Development of Therapeutics

Retrieved on: 
Mardi, février 14, 2023
Consensus, Rheumatology, Human, Physician, Monash University, SLE, Therapy, ALPHA, Lupus Foundation of America, Feedback, Drug development, Consultant, Patient, Hospital, Clinical trial, LFA, Food, Health, Brigham and Women's Hospital, Disease, FDA, MPH, Consensus decision-making, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GAC, Pharmaceutical industry, Dietary supplement, Medical device, Risk management, Lupus, MD

To address the urgent need to develop therapeutic solutions, the Addressing Lupus Pillars for Health Advancement (ALPHA) Project Global Advisory Committee (GAC) is recommending significant changes to lupus clinical trial outcome measures.

Key Points: 
  • To address the urgent need to develop therapeutic solutions, the Addressing Lupus Pillars for Health Advancement (ALPHA) Project Global Advisory Committee (GAC) is recommending significant changes to lupus clinical trial outcome measures.
  • In a new report, " The ALPHA Project: A Stakeholder Meeting on Lupus Clinical Trial Outcome Measures and the Patient Perspective ," published in Lupus Science & Medicine, the GAC and other key experts discuss how lupus disease complexity dictates necessary changes to clinical trial outcome measures, including incorporating patient voice and preference, to facilitate drug development progress.
  • "Consensus across the lupus community to simplify and standardize clinical trial outcome measures would provide a more promising avenue for evaluating the success of interventions for various lupus subtypes across age groups.
  • To improve lupus therapeutics development, experts agree on the following:
    Approaches to outcome measure development should be patient-centric and take into consideration factors most important to patients regarding their health.